Clinical trials: MTOR
TSC1, TSC2
Everolimus for Cancer With TSC1 or TSC2 Mutation
In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.
- Conditions
- TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
- Trial name
- NCT02201212
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Renal Cell Carcinoma
Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib
This is a nation-wide retrospective observational study which will be performed in 50 centres in Spain, geographically representative of all regions, with at least 5 patients treated with first-line pazopanib for mRCC in daily…
- Trial name
- Spazo-2 (NCT03091465)
- Where
- 57 sites in Spain
- Volunteers
- 530 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Renal Cell Carcinoma
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
The purpose of this study is to test the safety and efficacy of the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with metastatic kidney cancer.
- Trial name
- NCT00353301
- Testing
- Erlotinib hydrochloride, Sirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Colorado, Denver
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Gallbladder Cancer
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Gallbladder cancer (GBC) is the most common malignant tumour of the biliary tract. It is also the most aggressive cancer of the biliary tract with the shortest median survival from the time of diagnosis.
- Trial name
- NCT05833815
- Testing
- Everolimus 10 mg, Standard of care
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Banaras Hindu University
Inflammatory Bowel Diseases
Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis
Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering properties.
- Trial name
- NCT05567068
- Testing
- Atorvastatin 80mg, Mesalamine
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Tanta University
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth.
- Conditions
- PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly
- Trial name
- COSY (NCT05563831)
- Testing
- national registry
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Metastatic Castration-Resistant Prostate Cancer
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past.
- Trial name
- NCT02091531
- Testing
- MLN0128
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Malignant Lymphoma
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma.
- Conditions
- Solid Tumor, Malignant Lymphoma, Tumor
- Trial name
- NCT01473095
- Testing
- ARQ 092
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Soft-tissue Sarcoma
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
This is an open-label phase II study of TAK-228 for patients ≥ 18 years of age with complex genomic sarcomas exhibiting Phosphoinositide-3 Kinase (PI3K) pathway dysregulation.
- Trial name
- NCT02987959
- Testing
- TAK-228
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Tuberous Sclerosis Complex, Epilepsy
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
- Trial name
- TSC-STEPS (NCT05104983)
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Darcy Krueger
Lymphoma
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well everolimus works in treating older patients with mantle cell…
- Trial name
- NCT00727207
- Testing
- everolimus
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Technical University of Munich
Atherosclerosis
High Protein Diet and Atherosclerosis
Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality.
- Trial name
- HPA (NCT05235464)
- Testing
- Standard meal, High animal protein meal, High plant protein meal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
AML
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the addition of Sirolimus (rapamycin) to standard chemotherapy for the treatment of patients with high risk acute myelogenous leukemia (AML).
- Trial name
- NCT01184898
- Testing
- Sirolimus, Mitoxantrone, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Adult-Onset Still's Disease
Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
This study aims to further evaluate the anti-inflammatory effects of the mTOR inhibitor sirolimus in patients with adult-onset Still's disease (AOSD), and to verify whether it can reduce inflammation and control disease activity…
- Trial name
- NCT07151157
- Testing
- add-on sirolimus therapy
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
This is a Phase 1 dose escalation study of an investigational agent, everolimus, given in combination with standard radiation therapy, in prostate cancers with a rising PSA following a prostatectomy.
- Trial name
- NCT01548807
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Kidney Cancer
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also block blood flow to the tumor.
- Trial name
- NCT00331409
- Testing
- Everolimus, imatinib mesylate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute